Biopharmaceutical companies are harnessing AI to accelerate drug discovery and optimize diagnostics. A collaboration including AbbVie, Johnson & Johnson, Bristol Myers Squibb, Takeda, and Astex Pharmaceuticals pooled proprietary structural data to train large language models, enhancing prediction of protein-ligand interactions. Separately, Predicta Biosciences raised $23.4 million to expand its platform for blood cancer and autoimmune disease diagnostics using genomic and immune profiling, underscoring AI's transformative impact in precision medicine.